Cure My Disease

Don't miss your cure!

 Log in / Sign up

New bladder cancer drug shows promise in early trial

NCT ID NCT06637423

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with a type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder through a catheter. The main goals are to find the safest dose and see if people can tolerate it. About 32 participants with recurrent low-grade tumors will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002)

    RECRUITING

    Sherbrooke, Quebec, J1H 5N4, Canada

    Contact Phone: •••-•••-••••

  • Erasmus Medisch Centrum ( Site 0032)

    RECRUITING

    Rotterdam, South Holland, 3015 GD, Netherlands

    Contact Phone: •••-•••-••••

  • Gustave Roussy ( Site 0013)

    ACTIVE_NOT_RECRUITING

    Villejuif, Val-de-Marne, 94805, France

  • HENRI MONDOR HOSPITAL ( Site 0011)

    ACTIVE_NOT_RECRUITING

    Créteil, Val-de-Marne, 94010, France

  • Hospital Universitario 12 de Octubre ( Site 0042)

    RECRUITING

    Madrid, 28041, Spain

    Contact Phone: •••-•••-••••

  • Hospital Universitario Virgen de la Victoria ( Site 0043)

    RECRUITING

    Málaga, Andalusia, 29010, Spain

    Contact Phone: •••-•••-••••

  • Hôpital Claude Huriez ( Site 0012)

    ACTIVE_NOT_RECRUITING

    Lille, Nord, 59037, France

  • Johns Hopkins University ( Site 0055)

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact Phone: •••-•••-••••

  • Michael G Oefelein Clinical Trials ( Site 0053)

    RECRUITING

    Bakersfield, California, 93301, United States

    Contact Phone: •••-•••-••••

  • Moffitt Cancer Center ( Site 0057)

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact Phone: •••-•••-••••

  • Northwestern University ( Site 0051)

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-••••

  • Princess Margaret Cancer Centre ( Site 0003)

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

    Contact Phone: •••-•••-••••

  • St Bartholomew s Hospital ( Site 0061)

    RECRUITING

    London, London, City of, EC1A 7BE, United Kingdom

    Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.